A Physician’s Take on the CLEAR Trial Data

Video

Brian Shimkus, MD, shares his opinion of data on lenvatinib and pembrolizumab from the CLEAR trial.

Tom Powles, MBBS, MRCP, MD: Hi, I'm Tom Powles. I'm an oncologist from London. I look after patients with urology cancers, particularly bladder and kidney cancer, which we're talking about today. Brian, would you like to introduce yourself?

Brian Shimkus, MD: Yes. I'm Brian Shimkus. I'm a physician in Austin, Texas; private practice in a multi-specialty group. I don't specialize in any particular kind of cancer, but I enjoy genitourinary cancers and work closely with a very large group close to us. I've always been fond of treating renal cell carcinoma.

Tom Powles, MBBS, MRCP, MD: Brian, we just saw Bob Watson present the CLEAR data published in New England Journal [of Medicine]. There's been a later data cut more recently. The data looked impressive, with the response rate above 70%. The hazard ratio for PFS in the 0.39, I think, and the OS survival data significant at about 0.70. The total RB profile was okay. I think these combinations are challenging to give, more challenging than the single agent therapy, certainly. What was your take on the data overall in the paper?

Brian Shimkus, MD: I think it's amazing. If you look back, I've been practicing for about 20 years and going from renal cell carcinoma as a disease with interleukin therapy as the only option to something where we have all of these options, and now can decide how we want to treat people based on side effect profiles. It really gives them a bright outcome now. I've gone from treating people with single agents to getting better at treatment with multi-agent therapy. I think that really is the key here, as I see in this study. That's one of the big take-away points, is that the better you get at this, the more experience you have with multi-agent therapy, the better your patients are going to do. It becomes critical to understand how best to use these drugs, not just knowing which drugs are available.

Transcript edited for clarity.

Recent Videos
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Related Content
Phase 3 data support benmelstobart/anlotinib as a new potential standard in the frontline treatment of patients with advanced renal cell carcinoma.

Benmelstobart Combo Improves Outcomes Vs Sunitinib in Advanced RCC

Kyle Doherty
September 19th 2024
Article

Phase 3 data support benmelstobart/anlotinib as a new potential standard in the frontline treatment of patients with advanced renal cell carcinoma.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.

Belzutifan Significantly Improves PFS Vs Everolimus in Clear Cell RCC

Russ Conroy
September 4th 2024
Article

Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Patients receiving immune checkpoint inhibitors for renal cell carcinoma had improved symptom burden when enrolled in a remote exercise program.

Exercise Oncology May Improve HRQOL in Metastatic RCC

Ariana Pelosci
July 30th 2024
Article

Patients receiving immune checkpoint inhibitors for renal cell carcinoma had improved symptom burden when enrolled in a remote exercise program.

Belzutifan Improves PFS Across Subgroups for Advanced ccRCC

Belzutifan Improves PFS Across Subgroups for Advanced ccRCC

Ashling Wahner
July 12th 2024
Article

“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.